Pharmassetx
PharmassêtX is developing galenexib, a patented small molecule drug targeting the underlying mechanisms of chronic inflammation across multiple disease areas. The therapy initially targets pouchitis and has received FDA Orphan Drug designation, providing seven years of U.S. market exclusivity upon approval. The company projects $275 million in first-year revenue (2029) from this multi-indication therapeutic platform.
- Drug Discovery & Therapeutics
- Healthcare Technology
- Biotechnology
Funding
Founders
Founder details are not available yet.
Product
Problem
Current treatments for chronic inflammatory diseases primarily offer symptomatic relief rather than disease modification, leaving high unmet patient need. Drug development is often slow, indication-specific, and costly, and these conditions drive healthcare costs into the hundreds of billions annually in the U.S. alone, with 65 million Americans suffering from autoimmune and neurodegenerative diseases.
Solution
PharmassêtX provides galenexib, a patented small molecule drug designed to target the underlying mechanisms of chronic inflammation across multiple disease areas. The therapy initially targets pouchitis, a chronic inflammatory condition, and has received FDA Orphan Drug designation, offering seven years of market exclusivity. The company is developing galenexib as a single asset applicable across inflammatory bowel disease, autoimmune diseases, neurodegenerative diseases, viral and infectious diseases, and metabolic and cardiovascular diseases. This multi-market approach positions the drug as a broad therapeutic platform rather than a single-indication treatment.
Target Audience
Primary customers are gastroenterologists, immunologists, and specialty care providers treating patients with chronic inflammatory diseases, with an initial focus on the pouchitis patient population. Pharmaceutical distributors and healthcare systems serving this segment are secondary targets.
Features
- Patented small molecule with FDA Orphan Drug designation for pouchitis
- Seven years of U.S. market exclusivity upon approval
- Multi-indication potential spanning IBD, autoimmune, neurodegenerative, viral, metabolic, and cardiovascular diseases
- U.S.-based supply chain and manufacturing infrastructure
- Projected $275 million revenue in the first launch year (2029) with over $100 million risk-adjusted net present value